Scientists are rapidly advancing vaccine development beyond traditional mRNA approaches, with DNA origami nanotechnology emerging as a promising alternative. While mRNA vaccines have proven effective against COVID-19 and are being trialed for other infectious diseases (influenza, RSV, HIV, Zika, tuberculosis), limitations in performance, manufacturing, and storage have spurred research into more stable and versatile platforms. The new DoriVac platform addresses these challenges directly.
Зміст
mRNA Vaccine Limitations: A Need for Innovation
Current mRNA vaccines face hurdles in sustained protection, as viral evolution necessitates frequent updates to match emerging variants. Manufacturing complexity and high costs, coupled with strict cold-chain requirements, also pose logistical difficulties, especially in resource-constrained regions. These factors underscore the need for a vaccine platform that offers greater stability, ease of production, and broader immune responses.
Introducing DoriVac: A Nanotechnology-Based Solution
Researchers at Harvard University’s Wyss Institute and Dana-Farber Cancer Institute have developed DoriVac, a DNA origami-based vaccine that functions as both the antigen carrier and an adjuvant – a substance that enhances immune response. This platform leverages nanoscale precision to control vaccine composition and target specific immune cells more effectively.
The initial studies focused on HR2, a conserved peptide region found in the spike proteins of viruses like SARS-CoV-2, HIV, and Ebola. In preclinical trials with mice, DoriVac vaccines elicited robust antibody and T cell responses. Crucially, when tested in a human lymph node-on-a-chip model, the vaccines generated strong antigen-specific immune activation in human cells, mirroring expected responses in live subjects.
DoriVac vs. mRNA: A Comparative Advantage
In direct comparisons, DoriVac vaccines carrying the same SARS-CoV-2 spike protein variant demonstrated comparable immune activation to mRNA lipid nanoparticle (LNP) vaccines. However, DoriVac offers distinct advantages : enhanced stability, simplified storage, and easier manufacturing. These benefits make it particularly valuable for global distribution and rapid response to emerging outbreaks.
“With the DoriVac platform, we have developed an extremely flexible chassis with a number of critical advantages, including an unprecedented control over vaccine composition,” stated William Shih, Ph.D., a pioneer of this technology. The platform’s versatility has been demonstrated through successful targeting of multiple viral antigens.
How DNA Origami Vaccines Are Built
DoriVac vaccines are constructed from self-assembling square DNA nanostructures. One side displays precisely arranged adjuvant molecules, while the opposite side presents target antigens such as viral peptides or proteins. This nanoscale arrangement optimizes immune stimulation, resulting in stronger responses compared to traditional formulations. Early studies showed that DoriVac vaccines outperformed non-origami versions in tumor-bearing mice, highlighting the platform’s adjuvant capabilities.
From Mouse Models to Human Simulations
To improve predictability, researchers tested DoriVac using a human lymph node-on-a-chip, which mimics the human immune system. Results showed that DoriVac activated human dendritic cells, increasing inflammatory cytokine production and enhancing T cell activation. This convergence of technologies dramatically raises the chances of success for a new class of vaccines.
Manufacturing and Future Implications
DoriVac’s simpler manufacturing process and reduced cold-chain requirements could make it more accessible, especially in under-resourced regions. The platform also exhibits a promising safety profile, according to recent studies.
The DoriVac platform is now being translated into clinical applications through DoriNano, a company cofounded by Yang (Claire) Zeng, M.D., Ph.D., who led the development effort.
DNA origami vaccines represent a significant advancement in vaccine technology, offering a more stable, versatile, and potentially more accessible solution to future infectious disease threats. The platform’s unique design and demonstrated efficacy suggest it could play a crucial role in global pandemic preparedness.
